ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback